GlassScriptPhysician profile
Robin P Gehris
NPI 1861495426
$583,217.43
in general payments reported to CMS, 2019-2025
22 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $6,172 · 2021: $16K · 2022: $64K · 2023: $137K · 2024: $186K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $379K · Travel and Lodging: $56K · Consulting Fee: $54K · Food and Beverage: $8,886 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $378,525.50 |
| Travel and Lodging | $56,001.89 |
| Consulting Fee | $54,397.50 |
| Food and Beverage | $8,886.28 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $272,473.85 | 2019-2025 | Dupixent |
| Genzyme Corporation | $197,426.38 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $58,602.74 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $42,545.19 | 2023-2025 | Ycanth |
| Incyte Corporation | $9,681.61 | 2021-2025 | Opzelura |
| Kowa Pharmaceuticals America, INC. | $650.00 | 2025 | Zoryve |
| Abbvie INC. | $337.20 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $299.50 | 2021-2025 | |
| Pfizer INC. | $255.74 | 2021-2025 | |
| Dermavant Sciences, INC. | $211.27 | 2022-2024 | Vtama |
| Ucb, INC. | $124.99 | 2025 | Bimzelx |
| Leo Pharma INC. | $120.13 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $92.10 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $83.10 | 2022-2023 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $73.28 | 2021-2025 | Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.62 | 2025 | Vtama |
| Almirall LLC | $45.95 | 2021-2022 | |
| Krystal Biotech INC | $45.56 | 2024 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.74 | 2025 | Spevigo |
| Nobelpharma America, LLC | $23.70 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.67 | 2024 | Arazlo, Cabtreo, Jublia |
| Novartis Pharmaceuticals Corporation | $19.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Gehris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.